Cognition Therapeutics Inc. has announced positive topline results from its Phase 2 SEQUEL study of CT1812 in patients with mild-to-moderate Alzheimer's disease. The study showed a positive treatment effect of CT1812 on global and regional brain activity, as measured by quantitative electroencephalogram (qEEG). The results indicated a reduction in relative theta power and increased connectivity between brain regions in participants treated with CT1812.
The SEQUEL study, conducted in the Netherlands, met its primary endpoints for safety and tolerability. It assessed changes in brain wave patterns over four weeks of treatment and found that CT1812-treated participants experienced a decrease in relative theta power compared to the placebo period. Although not statistically significant, these findings suggest a positive impact on underlying brain function.
In addition to global measures of brain activity, the study also examined changes in frontal, central, temporal, and posterior regions. Treatment with CT1812 was associated with decreases in relative theta